Unknown

Dataset Information

0

Disrupting N-Glycosylation Using Type I Mannosidase Inhibitors Alters B-Cell Receptor Signaling.


ABSTRACT: Kifunensine is a known inhibitor of type I α-mannosidase enzymes and has been shown to have therapeutic potential for a variety of diseases and application in the expression of high-mannose N-glycan bearing glycoproteins; however, the compound's hydrophilic nature limits its efficacy. We previously synthesized two hydrophobic acylated derivatives of kifunensine, namely, JDW-II-004 and JDW-II-010, and found that these compounds were over 75-fold more potent than kifunensine. Here we explored the effects of these compounds on different mice and human B cells, and we demonstrate that they affected the cells in a similar fashion to kifunensine, further demonstrating their functional equivalence to kifunensine in assays utilizing primary cells. Specifically, a dose-dependent increase in the formation of high-mannose N-glycans decorated glycoproteins were observed upon treatment with kifunensine, JDW-II-004, and JDW-II-010, but greater potency was observed with the acylated derivatives. Treatment with kifunensine or the acylated derivatives also resulted in impaired B-cell receptor (BCR) signaling of the primary mouse B cells; however, primary human B cells treated with kifunensine or JDW-II-004 did not affect BCR signaling, while a modest increase in BCR signaling was observed upon treatment with JDW-010. Nevertheless, these findings demonstrate that the hydrophobic acylated derivatives of kifunensine can help overcome the mass-transfer limitations of the parent compound, and they may have applications for the treatment of ERAD-related diseases or prove to be more cost-effective alternatives for the generation and production of high-mannose N-glycan bearing glycoproteins.

SUBMITTER: Huang A 

PROVIDER: S-EPMC9667535 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Disrupting N-Glycosylation Using Type I Mannosidase Inhibitors Alters B-Cell Receptor Signaling.

Huang Aric A   Kurhade Suresh E SE   Ross Patrick P   Apley Kyle D KD   Griffin Jonathan Daniel JD   Berkland Cory J CJ   Farrell Mark P MP  

ACS pharmacology & translational science 20221025 11


Kifunensine is a known inhibitor of type I α-mannosidase enzymes and has been shown to have therapeutic potential for a variety of diseases and application in the expression of high-mannose N-glycan bearing glycoproteins; however, the compound's hydrophilic nature limits its efficacy. We previously synthesized two hydrophobic acylated derivatives of kifunensine, namely, JDW-II-004 and JDW-II-010, and found that these compounds were over 75-fold more potent than kifunensine. Here we explored the  ...[more]

Similar Datasets

| S-EPMC8131250 | biostudies-literature
| S-EPMC9052946 | biostudies-literature
| S-EPMC5025693 | biostudies-literature
| S-EPMC7933808 | biostudies-literature
| S-EPMC3589671 | biostudies-literature
| S-EPMC3847306 | biostudies-literature
| S-SCDT-10_1038-S44321-024-00085-3 | biostudies-other
| S-EPMC6208381 | biostudies-literature
| S-EPMC6889143 | biostudies-literature
| S-EPMC7703563 | biostudies-literature